Emiliano Barbieri

Hematogy Specialist at AUSL-IRCCS of Reggio Emilia.
PhD student in Clinical and Experimental Medicine at UNIMORE.
Founder of Congresso MoReMED.

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: +1q retains prognostic significance in era of daratumumab-based treatments; isolated +1q remains independent factor of adverse prognosis (e.g. shorter PFS (HR 4.77) & TTNT (3.83), further worsened by co-existing HiRCAs: https://t.co/WTvyzMhzxP. #mmsm

[Emiliano Barbieri @EmBarbieriMD]

Thrilled to share the publication of our latest work in Multiple Myeloma!

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens - Barbieri - European Journal of Haematology - Wiley Online Library https://t.co/VxUaZCUAXb

[CLLMonitor @CllMonitor]

📌 𝐑𝐢𝐬𝐮𝐥𝐭𝐚𝐭𝐢 𝐞 𝐜𝐨𝐦𝐦𝐞𝐧𝐭𝐨 𝐝𝐞𝐥 #𝐂𝐀𝐒𝐎𝐂𝐋𝐈𝐍𝐈𝐂𝐎: 𝐖𝐀𝐑𝐌 𝐀𝐔𝐓��𝐈𝐌𝐌𝐔𝐍𝐄 #𝐇𝐄𝐌𝐎𝐋𝐘𝐓𝐈𝐂𝐀𝐍𝐄𝐌𝐈𝐀 𝐈𝐍 𝐏𝐀𝐙𝐈𝐄𝐍𝐓𝐄 𝐂��𝐍 #𝐂𝐋𝐋
𝐒��𝐨𝐩𝐫𝐢 𝐢 𝐫𝐢𝐬𝐮𝐥𝐭𝐚𝐭𝐢 𝐬𝐮𝐥 𝐬𝐢𝐭𝐨 👉 https://t.co/V23yXcXASo

[CLLMonitor @CllMonitor]

📌 𝐂𝐀𝐒𝐎 𝐂𝐋𝐈𝐍𝐈𝐂𝐎: 𝐖𝐀𝐑𝐌 𝐀𝐔𝐓𝐎𝐈𝐌𝐌𝐔𝐍𝐄 𝐇𝐄𝐌𝐎𝐋𝐘𝐓𝐈𝐂 #𝐀𝐍𝐄𝐌𝐈𝐀 𝐈𝐍 𝐏��𝐙𝐈𝐄𝐍𝐓𝐄 𝐂𝐎𝐍 #𝐂𝐋𝐋
Partecipa al sondaggio di questa settimana 👇 𝐛𝐚𝐬𝐭𝐚 𝐮𝐧 𝐜𝐥𝐢𝐜𝐤
👉 https://t.co/5v2NzxvNkr

#cllmonitor #leukemia #leucemia #hemolyticanemia

[CLLMonitor @CllMonitor]

📌 𝐂𝐀𝐒𝐎 𝐂𝐋𝐈𝐍𝐈𝐂𝐎: 𝐔𝐍 𝐑𝐀𝐌𝐏-𝐔𝐏 𝐂𝐎𝐌𝐏𝐋𝐈𝐂𝐀𝐓𝐎
Partecipa al sondaggio di questa settimana 👇 𝐛𝐚𝐬𝐭𝐚 𝐮𝐧 𝐜𝐥𝐢𝐜𝐤
👉 https://t.co/xNewcIE6hD

#cll #leukemia #leucemia #cllmonitor

[CLLMonitor @CllMonitor]

📌 𝐂𝐀𝐒𝐎 𝐂𝐋𝐈𝐍𝐈𝐂𝐎: 𝐒𝐋𝐈𝐃𝐈𝐍𝐆 𝐃𝐎𝐎𝐑𝐒 𝐍𝐄𝐋𝐋𝐀 𝐓𝐄𝐑𝐀𝐏𝐈𝐀 𝐃𝐈 𝐏𝐑𝐈𝐌𝐀 𝐋𝐈𝐍𝐄𝐀
Partecipa al sondaggio di questa settimana 👇
👉 https://t.co/uEV0hHMFqI

#cllmonitor #CLL #leukemia #primalinea

[Emiliano Barbieri @EmBarbieriMD]

Now published our last work, check it out!

Effects of the BTN162b2 mRNA COVID‐19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia. https://t.co/4TNhjsgNdE

[Emiliano Barbieri @EmBarbieriMD]

https://t.co/ITGCmSWgVQ
Our last work on Multiple Myeloma, check it out!

[CLLMonitor @CllMonitor]

📌 𝐂𝐀𝐒𝐎 𝐂𝐋𝐈𝐍𝐈𝐂𝐎: #𝐓𝐄𝐑𝐀𝐏𝐈𝐀 𝐃𝐈 𝐏𝐑��𝐌𝐀 𝐋𝐈𝐍𝐄𝐀 𝐄 𝐂𝐎𝐌𝐎𝐑𝐁𝐈𝐃𝐈𝐓𝐀̀
Partecipa al sondaggio di questa settimana 👇
👉 https://t.co/bZ9QPoWZ7O

#cllmonitor #leucemia #Leukemia #CLL

[Paperbirds_Hematology @PaperbirdsM]

New article: Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience https://t.co/aIWTZbMwl0 #MMSM #MultipleMyeloma #hematology